DPYD and breast carcinoma: Nonetheless, the usefulness of a genetic screening is exemplified by DPYD genotyping already in use in the clinic to predict severe and lethal capecitabine toxicity in breast cancer patients based on the presence of the most common deleterious polymorphism in dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of the drug [34, 35].